NasdaqCM - Nasdaq Real Time Price USD

Vivos Therapeutics, Inc. (VVOS)

2.6300

-0.0800

(-2.95%)

At close: April 25 at 4:00:00 PM EDT

2.7100

+0.08

+(3.04%)

After hours: April 25 at 4:13:52 PM EDT

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced a definitive agreement to acquire

GlobeNewswire 10 days ago

VVOS
-2.95%
Vivos Therapeutics Inc (VVOS) Q4 2024 Earnings Call Highlights: Strategic Shifts Propel Revenue ...

Vivos Therapeutics Inc (VVOS) reports a 26% increase in product revenue and a 35% reduction in operating loss, driven by strategic expansions and new marketing alliances.

GuruFocus.com 24 days ago

VVOS
-2.95%
Vivos Therapeutics Full Year 2024 Earnings: Misses Expectations

Vivos Therapeutics ( NASDAQ:VVOS ) Full Year 2024 Results Key Financial Results Revenue: US$15.0m (up 8.9% from FY...

Simply Wall St. 24 days ago

VVOS
-2.95%
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates

Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of 34.88% and 5.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 26 days ago

VVOS
-2.95%
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all

GlobeNewswire 26 days ago

VVOS
-2.95%
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Call Scheduled for Monday, March 31, 2025 at 5:00 pm ETLITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today a

GlobeNewswire 29 days ago

VVOS
-2.95%
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide

Vivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea patients prefer Vivos CARE treatment for OSA nearly 2 to 1 over CPAP Vivos seeking additional alliances or acquisitions of sleep medicine practices to fuel national expansion objectives LITTLETON, Colo., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in novel, non-invasive obstructive sleep apnea (

GlobeNewswire last month

VVOS
-2.95%
Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET.

LITTLETON, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced that the Company’s CEO Kirk Huntsman will part

GlobeNewswire 2 months ago

VVOS
-2.95%
Best Momentum Stocks to Buy for January 8th

VVOS, DXC and YELP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.

Zacks 3 months ago

YELP

VVOS
-2.95%
DXC
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced that it has entered into definitive agreements

GlobeNewswire 4 months ago

VVOS
-2.95%
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy

Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 4 months ago

VVOS
-2.95%
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Vivos Therapeutics ( NASDAQ:VVOS ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.86m (up 17% from 3Q...

Simply Wall St. 5 months ago

VVOS
-2.95%
Vivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Vivos Therapeutics Inc (VVOS) reports strong revenue growth and strategic advancements, despite facing increased net losses and market uncertainties.

GuruFocus.com 5 months ago

VVOS
-2.95%
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring

GlobeNewswire 5 months ago

VVOS
-2.95%
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Call Scheduled for Thursday, November 14, 2024 at 5:00 pm ETLITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its third quarter 2024 financi

GlobeNewswire 5 months ago

VVOS
-2.95%
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and ChildrenLITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including obstructive sleep apnea (OSA) in adults and children, today announc

GlobeNewswire 6 months ago

VVOS
-2.95%
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe in children), announced today that it has entered into definitive securities purchase agreements with in

GlobeNewswire 7 months ago

VVOS
-2.95%
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children. Recent published studies report up to 10.1 million U.S. children (ages 6-17) are estimated to suffer from pediatric OSA. Vivos’ DNA appliance is non-invasive, safe, comfortable, affordable, and highly effective. It is designed to reduce nighttime snoring and treat moderate to sever

Benzinga 7 months ago

VVOS
-2.95%
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now approved to reduce snoring and treat moderate to severe OSA in children aged 6 to 17 LITTLETON, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercializati

GlobeNewswire 7 months ago

VVOS
-2.95%
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective p

GlobeNewswire 8 months ago

VVOS
-2.95%

Performance Overview

Return	VVOS	S&P 500 (^GSPC)
YTD	-38.69%	-6.06%
1-Year	+6.91%	+9.44%
3-Year	-93.95%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

Vivos Therapeutics Inc (VVOS) Q4 2024 Earnings Call Highlights: Strategic Shifts Propel Revenue ...

Vivos Therapeutics Full Year 2024 Earnings: Misses Expectations

Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide

Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET.

Best Momentum Stocks to Buy for January 8th

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy

Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Vivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Performance Overview